ISU Abxis Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
185
- Stock Symbol
-
086890
- Share Price
-
$2.38
- (As of Tuesday Closing)
ISU Abxis General Information
Description
ISU Abxis Co Ltd is engaged in developing and manufacturing therapeutic antibodies in South Korea. It offers Abciximab, Clotinab, Abcertin, and Fabagal used to treat incurable diseases such as cancer and rare diseases.
Contact Information
Website
www.abxis.comCorporate Office
- Global R&D Center Building C, 4th, 5th Floor
- 22 Daewangpangyo-ro 712beon-gil
- Seongnam, Gyeonggi 13488
- South Korea
Corporate Office
- Global R&D Center Building C, 4th, 5th Floor
- 22 Daewangpangyo-ro 712beon-gil
- Seongnam, Gyeonggi 13488
- South Korea
ISU Abxis Stock Performance
As of 17-Nov-2026, ISU Abxis’s stock price is $2.38. Its current market cap is $97M with 40.8M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.38 | $2.31 | $1.94 - $4.32 | $97M | 40.8M | 68.7K | -$0.15 |
ISU Abxis Financials Summary
As of 30-Jun-2026, ISU Abxis has a trailing 12-month revenue of $35.2M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 94,995 | 140,365 | 104,397 | 147,296 |
| Revenue | 35,170 | 39,822 | 44,164 | 41,535 |
| EBITDA | 555 | (479) | 5,170 | 13,228 |
| Net Income | (5,637) | (7,503) | 10,787 | 2,762 |
| Total Assets | 99,926 | 110,343 | 108,781 | 160,427 |
| Total Debt | 14,069 | 20,422 | 29,784 | 87,884 |
ISU Abxis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ISU Abxis Patents
ISU Abxis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023386332-A1 | Antibody binding specifically to asm protein | Pending | 25-Nov-2022 | ||
| EP-4624495-A1 | Antibody binding specifically to asm protein | Pending | 25-Nov-2022 | ||
| US-20260201064-A1 | Antibody binding specifically to asm protein | Pending | 25-Nov-2022 | ||
| WO-2024111990-A1 | Antibody binding specifically to asm protein | Inactive | 25-Nov-2022 | ||
| AU-2022279876-A1 | Antibody specifically binding to asm protein | Active | 27-May-2021 | G01N33/573 |
ISU Abxis Signals
ISU Abxis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ISU Abxis ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
ISU Abxis FAQs
-
When was ISU Abxis founded?
ISU Abxis was founded in 2001.
-
Where is ISU Abxis headquartered?
ISU Abxis is headquartered in Seongnam, South Korea.
-
What is the size of ISU Abxis?
ISU Abxis has 185 total employees.
-
What industry is ISU Abxis in?
ISU Abxis’s primary industry is Drug Discovery.
-
Is ISU Abxis a private or public company?
ISU Abxis is a Public company.
-
What is ISU Abxis’s stock symbol?
The ticker symbol for ISU Abxis is 086890.
-
What is the current stock price of ISU Abxis?
As of 17-Nov-2026 the stock price of ISU Abxis is $2.38.
-
What is the current market cap of ISU Abxis?
The current market capitalization of ISU Abxis is $97M.
-
What is ISU Abxis’s current revenue?
The trailing twelve month revenue for ISU Abxis is $35.2M.
-
What is ISU Abxis’s annual earnings per share (EPS)?
ISU Abxis’s EPS for 12 months was -$0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process